Latest & greatest articles for HIV Test

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on HIV Test or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on HIV Test and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for HIV Test

1. HIV self-testing in high-income settings: Acceptability, potential benefits and harms, issues related to linkage to care, interventions to increase HIV self-testing

HIV self-testing in high-income settings: Acceptability, potential benefits and harms, issues related to linkage to care, interventions to increase HIV self-testing HIV self-testing in high-income settings: Acceptability, potential benefits and harms, issues related to linkage to care, interventions to increase HIV self-testing | The Ontario HIV Treatment Network The Ontario HIV Treatment Network HIV self-testing in high-income settings: Acceptability, potential benefits and harms, issues (...) related to linkage to care, interventions to increase HIV self-testing HIV self-testing in high-income settings: Acceptability, potential benefits and harms, issues related to linkage to care, interventions to increase HIV self-testing , , , , , Questions What is the current evidence in high-income settings on HIV self-testing related to acceptability, potential benefits and harms, issues related to the linkage to care after a positive test, and interventions to increase HIV self-testing? Key take

2019 Ontario HIV Treatment Network

2. The risk of coercion in the context of HIV self-testing

The risk of coercion in the context of HIV self-testing The risk of coercion in the context of HIV self-testing | The Ontario HIV Treatment Network The Ontario HIV Treatment Network The risk of coercion in the context of HIV self-testing The risk of coercion in the context of HIV self-testing , , , Questions What evidence is available on risk of coercion in the context of HIV self-testing? Key take-home messages While studies to date indicate that there are many benefits of HIV self-testing (...) (also known as home-testing) and the risk of harm through coerced self-testing is minimal, the risk of coercion still exists (1). HIV home testing in high-income settings is seen as less problematic because it is assumed that individuals would be able to pay for the test, do the test, and experience the testing process in a context free from coercion or abuse (2, 3). In high-income settings, HIV self-testing may be less challenging because existing systems ensure proper regulation, access to health

2019 Ontario HIV Treatment Network

3. Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART). (PubMed)

Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART). A universal testing and treatment strategy is a potential approach to reduce the incidence of human immunodeficiency virus (HIV) infection, yet previous trial results are inconsistent.In the HPTN 071 (PopART) community-randomized trial conducted from 2013 through 2018, we randomly assigned 21 communities in Zambia and South Africa (total population, approximately 1 million) to group A (combination prevention (...) intervention with universal antiretroviral therapy [ART]), group B (the prevention intervention with ART provided according to local guidelines [universal since 2016]), or group C (standard care). The prevention intervention included home-based HIV testing delivered by community workers, who also supported linkage to HIV care and ART adherence. The primary outcome, HIV incidence between months 12 and 36, was measured in a population cohort of approximately 2000 randomly sampled adults (18 to 44 years

Full Text available with Trip Pro

2019 NEJM Controlled trial quality: predicted high

4. Universal Testing, Expanded Treatment, and Incidence of HIV Infection in Botswana. (PubMed)

Universal Testing, Expanded Treatment, and Incidence of HIV Infection in Botswana. The feasibility of reducing the population-level incidence of human immunodeficiency virus (HIV) infection by increasing community coverage of antiretroviral therapy (ART) and male circumcision is unknown.We conducted a pair-matched, community-randomized trial in 30 rural or periurban communities in Botswana from 2013 to 2018. Participants in 15 villages in the intervention group received HIV testing (...) and counseling, linkage to care, ART (started at a higher CD4 count than in standard care), and increased access to male circumcision services. The standard-care group also consisted of 15 villages. Universal ART became available in both groups in mid-2016. We enrolled a random sample of participants from approximately 20% of households in each community and measured the incidence of HIV infection through testing performed approximately once per year. The prespecified primary analysis was a permutation test

Full Text available with Trip Pro

2019 NEJM Controlled trial quality: uncertain

5. HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa. (PubMed)

HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa. Universal antiretroviral therapy (ART) with annual population testing and a multidisease, patient-centered strategy could reduce new human immunodeficiency virus (HIV) infections and improve community health.We randomly assigned 32 rural communities in Uganda and Kenya to baseline HIV and multidisease testing and national guideline-restricted ART (control group) or to baseline testing plus annual testing (...) ). At 3 years, 47% of adults with hypertension in the intervention group and 37% in the control group had hypertension control (relative prevalence, 1.26; 95% CI, 1.15 to 1.39).Universal HIV treatment did not result in a significantly lower incidence of HIV infection than standard care, probably owing to the availability of comprehensive baseline HIV testing and the rapid expansion of ART eligibility in the control group. (Funded by the National Institutes of Health and others; SEARCH

2019 NEJM Controlled trial quality: predicted high

6. Strategies to link people with undiagnosed HIV infection to HIV testing, care, and prevention services

Strategies to link people with undiagnosed HIV infection to HIV testing, care, and prevention services Strategies to link people with undiagnosed HIV infection to HIV testing, care, and prevention services | The Ontario HIV Treatment Network The Ontario HIV Treatment Network Strategies to link people with undiagnosed HIV infection to HIV testing, care, and prevention services Strategies to link people with undiagnosed HIV infection to HIV testing, care, and prevention services , , , , Questions (...) What strategies have been successful at linking people with undiagnosed HIV infection to HIV testing, care, and prevention services? Key take-home messages A variety of strategies have shown promise for identifying individuals with undiagnosed HIV and engaging them with HIV testing using clinical, community-based, network-based, and self-directed approaches. Various service delivery models for implementing rapid initiation of antiretroviral treatment have demonstrated benefits for linking the newly

2019 Ontario HIV Treatment Network

7. A cross-jurisdictional review of HIV testing intervals for population groups at high risk of HIV infection

A cross-jurisdictional review of HIV testing intervals for population groups at high risk of HIV infection A cross-jurisdictional review of HIV testing intervals for population groups at high risk of HIV infection | The Ontario HIV Treatment Network The Ontario HIV Treatment Network A cross-jurisdictional review of HIV testing intervals for population groups at high risk of HIV infection A cross-jurisdictional review of HIV testing intervals for population groups at high risk of HIV infection (...) , , , , , , , , , , Question At what intervals do high-income jurisdictions encourage population groups at high risk of HIV infection to come forward for routine testing? Key take-home messages Most guidelines recommend at least annual HIV testing of population groups at high risk of HIV infection. These include: men who have sex with men, transgender women and men, people who use injection drugs, African, Caribbean and Black communities, indigenous people, and women at risk. Some guidelines recommend more frequent

2019 Ontario HIV Treatment Network

8. HIV self-testing alone or with additional interventions, including financial incentives, and linkage to care or prevention among male partners of antenatal care clinic attendees in Malawi: An adaptive multi-arm, multi-stage cluster randomised trial

HIV self-testing alone or with additional interventions, including financial incentives, and linkage to care or prevention among male partners of antenatal care clinic attendees in Malawi: An adaptive multi-arm, multi-stage cluster randomised trial Conventional HIV testing services have been less comprehensive in reaching men than in reaching women globally, but HIV self-testing (HIVST) appears to be an acceptable alternative. Measurement of linkage to post-test services following HIVST remains (...) HIVST kits for their partners; the second and third arms provided 2 HIVST kits along with a conditional fixed financial incentive of $3 or $10; the fourth arm provided 2 HIVST kits and a 10% chance of receiving $30 in a lottery; and the fifth arm provided 2 HIVST kits and a phone call reminder for the women's partners. The primary outcome was the proportion of male partners who were reported to have tested for HIV and linked into care or prevention within 28 days, with referral for antiretroviral

Full Text available with Trip Pro

2019 EvidenceUpdates

9. Self-testing kits increase overall HIV testing uptake in men who have sex with men

Self-testing kits increase overall HIV testing uptake in men who have sex with men Self-testing kits increase overall HIV testing uptake in men who have sex with men Discover Portal Discover Portal Self-testing kits increase overall HIV testing uptake in men who have sex with men Published on 6 February 2018 doi: Frequency of HIV testing in men who have sex with men may be increased by one additional test in a six month period when self-testing kits are used. Self-testing kits allow people (...) and support following an HIV diagnosis are of great importance and should include partner notification. Self-testing kits are available in the UK online from and are recommended by Public Health England. Share your views on the research. Why was this study needed? An estimated 89,400 people in the UK are living with HIV according to 2016 figures. The annual rate of new diagnoses is starting to decline, falling from 6,286 in 2015 to 5,164 in 2016. Over half of cases are in men who have sex with men (MSM

2019 NIHR Dissemination Centre

10. Impact of opioid substitution therapy on HIV testing among people who have recently injected drugs: a systematic review and meta-analysis

Impact of opioid substitution therapy on HIV testing among people who have recently injected drugs: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration (...) will correct the total number of control animals in the meta-analysis by dividing the number of animals in the control group by the number of treatment groups served. Where applicable, Holm-Bonferroni correction for testing multiple subgroup analyses will be performed. If one or more subgroup analyses cannot be performed due to insufficient data, the p-value will be adjusted accordingly. ">Other Subgroup analysis or meta-regression are used to explore between-study heterogeneity and can provide insight

2019 PROSPERO

11. Verifying decentralized HIV self-testing use and results: a global systematic review

Verifying decentralized HIV self-testing use and results: a global systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites (...) by dividing the number of animals in the control group by the number of treatment groups served. Where applicable, Holm-Bonferroni correction for testing multiple subgroup analyses will be performed. If one or more subgroup analyses cannot be performed due to insufficient data, the p-value will be adjusted accordingly. ">Other Subgroup analysis or meta-regression are used to explore between-study heterogeneity and can provide insight into the relationship between study characteristics (e.g. species, sex

2019 PROSPERO

12. Optimal tests in diagnosing and monitoring diabetes in people living with HIV: protocol for a systematic review

Optimal tests in diagnosing and monitoring diabetes in people living with HIV: protocol for a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files (...) animals in the meta-analysis by dividing the number of animals in the control group by the number of treatment groups served. Where applicable, Holm-Bonferroni correction for testing multiple subgroup analyses will be performed. If one or more subgroup analyses cannot be performed due to insufficient data, the p-value will be adjusted accordingly. ">Other Subgroup analysis or meta-regression are used to explore between-study heterogeneity and can provide insight into the relationship between study

2019 PROSPERO

13. Point-of-care viral load tests to detect high HIV viral load levels in HIV-positive people on antiretroviral therapy [Cochrane protocol]

Point-of-care viral load tests to detect high HIV viral load levels in HIV-positive people on antiretroviral therapy [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration (...) will correct the total number of control animals in the meta-analysis by dividing the number of animals in the control group by the number of treatment groups served. Where applicable, Holm-Bonferroni correction for testing multiple subgroup analyses will be performed. If one or more subgroup analyses cannot be performed due to insufficient data, the p-value will be adjusted accordingly. ">Other Subgroup analysis or meta-regression are used to explore between-study heterogeneity and can provide insight

2019 PROSPERO

14. Point-of-care tests detecting HIV nucleic acids for diagnosis of HIV infection in infants and children aged 18 months or less [Cochrane protocol]

Point-of-care tests detecting HIV nucleic acids for diagnosis of HIV infection in infants and children aged 18 months or less [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content (...) experimental group, we will correct the total number of control animals in the meta-analysis by dividing the number of animals in the control group by the number of treatment groups served. Where applicable, Holm-Bonferroni correction for testing multiple subgroup analyses will be performed. If one or more subgroup analyses cannot be performed due to insufficient data, the p-value will be adjusted accordingly. ">Other Subgroup analysis or meta-regression are used to explore between-study heterogeneity

2019 PROSPERO

15. HIV testing as part of the prevention of mother to child transmission of HIV service among Ethiopian reproductive age-group women: a systematic review and meta-analysis

HIV testing as part of the prevention of mother to child transmission of HIV service among Ethiopian reproductive age-group women: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability (...) one experimental group, we will correct the total number of control animals in the meta-analysis by dividing the number of animals in the control group by the number of treatment groups served. Where applicable, Holm-Bonferroni correction for testing multiple subgroup analyses will be performed. If one or more subgroup analyses cannot be performed due to insufficient data, the p-value will be adjusted accordingly. ">Other Subgroup analysis or meta-regression are used to explore between-study

2019 PROSPERO

16. Public health guidance on HIV, hepatitis B and C testing in the EU/EEA

Public health guidance on HIV, hepatitis B and C testing in the EU/EEA SCIENTIFIC AD VICE www.ecdc.europa.eu Public health guidance on HIV, hepatitis B and C testing in the EU/EEA An integrated approachECDC SCIENTIFIC ADVICE Public health guidance on HIV, hepatitis B and C testing in the EU/EEA An integrated approach ii This guidance was commissioned by the European Centre for Disease Prevention and Control (ECDC), coordinated by Andrew J Amato-Gauci and Lara Tavoschi with the support of Helena (...) guidance on HIV, hepatitis B and C testing in the EU/EEA – An integrated approach. Stockholm: ECDC; 2018. Stockholm, November 2018 PDF Print ISBN 978-92-9498-286-5 ISBN 978-92-9498-294-0 DOI 10.2900/79127 DOI 10.2900/489464 Catalogue number TQ-06-18-328-EN-N Catalogue number TQ-06-18-328-EN-C © European Centre for Disease Prevention and Control, 2018 Cover picture: © iStock Reproduction is authorised, provided the source is acknowledged. For any use or reproduction of photos or other material

2019 European Centre for Disease Prevention and Control - Public Health Guidance

17. Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA

Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA Suggested citation: European Centre for Disease Prevention and Control. Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA – An integrated approach. Stockholm: ECDC; 2018. Stockholm, December 2018 Reproduction is authorised, provided the source is acknowledged. PDF Print ISBN 978-92-9498-291-9 ISBN 978-92-9498-292-6 DOI 10.2900/809892 DOI 10.2900/579896 Catalogue number TQ-06-18-361-EN-N (...) Catalogue number TQ-06-18-361-EN-C © European Centre for Disease Prevention and Control, Stockholm, 2018 Scope and purpose of guidance The ECDC guidance on integrated testing of hepatitis B (HBV), hepatitis C (HCV) and HIV supports countries in the global effort to combat viral hepatitis and eliminate HIV as public health threats by 2030. At present, reaching and testing those at risk of infection with HIV, HBV or HCV is still a public health challenge across Europe. Figure 1. The case for integrated

2019 European Centre for Disease Prevention and Control - Public Health Guidance

18. Methods, system errors, and demographic differences in participant errors using daily text message-based short message service computer-assisted self-interview (SMS-CASI) to measure sexual risk behavior in a RCT of HIV self-test use. (PubMed)

Methods, system errors, and demographic differences in participant errors using daily text message-based short message service computer-assisted self-interview (SMS-CASI) to measure sexual risk behavior in a RCT of HIV self-test use. Assessment of sexual risk behavior is crucial to HIV prevention trials. Currently, there are no biomarkers or objective measures to detect and characterize sexual risk behavior; therefore, we must rely on self-reports. Self-report accuracy may be improved (...) by collecting data in real-time. Our objective was to demonstrate how a text message-based short message service computer-assisted self-interview (SMS-CASI) system can collect daily sexual risk behavior data.During the course of a 2-arm randomized controlled trial, confidential daily SMS-CASI was used to assess sexual risk behavior over three months for participants using only condoms in the control condition and using condoms and HIV self-tests to test themselves and their non-monogamous sexual partner

Full Text available with Trip Pro

2019 mHealth Controlled trial quality: uncertain

19. Variations in Testing for HIV and Other Sexually Transmitted Infections Across Gender Identity Among Transgender Youth. (PubMed)

Variations in Testing for HIV and Other Sexually Transmitted Infections Across Gender Identity Among Transgender Youth. Purpose: Transgender youth are at high risk for human immunodeficiency virus (HIV) and other sexually transmitted infections (STIs), but their rates of screening are unknown. This study sought to quantify HIV and other STI testing levels and to examine variations in testing levels across three categories of gender identity: transgender men, transgender women, and nonbinary (...) individuals. Methods: Between June 2017 and June 2018, 186 transgender youth aged 15-24 years were recruited into a randomized trial of home HIV testing supplemented with telehealth-based counseling. Information on sociodemographics, health care utilization, sexual activity, stress and resilience, and history of HIV and other STI testing was obtained. Multivariable logistic regression models were formulated to identify variations in testing for HIV and other STIs across gender identities. Results: Twenty

Full Text available with Trip Pro

2019 Transgender health Controlled trial quality: uncertain

20. HIV self-testing at the workplace

HIV self-testing at the workplace POLICY BRIEF HIV TESTING SERVICES HIV SELF-TESTING AT THE WORKPLACE NOVEMBER 2018 Despite considerable scale-up of HIV testing services, many people are left behind, particularly men, adolescents, young women, and members of key populations 1 . Without further scale-up of strategies that make HIV testing services more convenient and appealing to those in need, it will be difficult to reach the United Nations 90–90–90 targets for 2020 – the first of which (...) is diagnosing 90% of all people with HIV. HIV self-testing (HIVST) is a testing option recommended by WHO that can be used to reach as-yet undiagnosed populations. According to the latest reports 2 , 59 countries have adopted HIVST policies as of June 2018, and many others are developing them. Photos clockwise: Re-Action, South Africa; Re-Action, South Africa; ILO; Sibanye-Stillwater, South Africa. 1 The WHO defines key populations as groups who, due to specific higher-risk behaviours and barriers

2018 World Health Organisation HIV Guidelines